Welcome to our dedicated page for THE TRENDLINES GRP SP/ADR news (Ticker: TRNLY), a resource for investors and traders seeking the latest updates and insights on THE TRENDLINES GRP SP/ADR stock.
The Trendlines Group SP/ADR (TRNLY) is a leading investment group based in Israel and Singapore, specializing in identifying, investing in, and developing technologies with high growth potential in the medical and agrifood sectors. Through strategic partnerships and collaborations, The Trendlines Group nurtures innovative startups, driving advancements in healthcare, agriculture, and sustainability. Recently, The Trendlines Group has been involved in funding breakthrough companies such as Vessi Medical, ZygoFix, Limaca, and Ceretrieve, supporting cutting-edge solutions for bladder cancer treatment, spinal fusion technology, endoscopic ultrasound biopsies, and stroke care.
Limaca Medical's Precision-GI™ endoscopic biopsy device has been granted transitional pass-through (TPT) payment by CMS, effective January 1, 2025, for up to three years. The device, which received FDA Breakthrough Device Designation in 2022 and FDA clearance in August 2023, is designed to improve biopsy results for gastrointestinal cancers. The motorized, automated rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass, enhancing diagnostic efficiency. The TPT program will support broader patient access by providing additional payments to hospitals to cover adoption costs. The device began its U.S. market entry in September 2024.
ElastiMed has appointed Dr. Amir Belson to its Board of Directors. Dr. Belson brings extensive experience in the medical device industry, having founded several successful companies including Neoguide Systems (acquired by Intuitive Surgical), Vascular Pathways (acquired by C.R. Bard), and Zipline Medical (acquired by Stryker). The appointment comes as ElastiMed prepares to bring its innovative compression therapy device to market. The company focuses on developing wearable medical devices for lymphatic and venous disease patients.
Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.
Arcuro Medical has announced a significant milestone, surpassing 4,000 surgical cases worldwide and 1,000 cases in the U.S. with its SuperBall™ Meniscal Repair System. The current version, launched in 2022 with line extensions in 2023, addresses a full range of meniscus tear patterns. CEO Jamal Rushdy expressed excitement about the achievement and future growth prospects.
Dr. Philip Davidson, Arcuro's Medical Director, highlighted the system's unique tensioning mechanism, which provides superior strength and reduced complications compared to other devices. Arcuro has recently made key hires in the U.S., including Jamal Rushdy as CEO and Nick Tonno as Sales Director, to focus on commercial growth. The company plans to provide updates at upcoming industry events in Las Vegas.
Dasyo, a pioneer in noninvasive medical aesthetics technologies, has appointed Domenic (Dom) Serafino as Executive Board Chair. Serafino brings extensive industry experience, having co-founded and led Venus Concept Inc. to over $100 million in annual revenues. He was also instrumental in Syneron Medical Corp's successful IPO. Dasyo, funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), is developing a groundbreaking non-surgical breast lift product using proprietary technology for noninvasive directional skin tightening. This appointment is expected to significantly enhance Dasyo's strategic direction and growth potential in the aesthetics medical device sector.
Ceretrieve announced successful results of its multicenter, single-arm study for its aspiration catheter, aimed at treating acute ischemic stroke (AIS) caused by large vessel occlusion (LVO).
The study involved 20 patients and achieved 100% Complete/Near-Complete Perfusion with the Gen 2 device, far exceeding the 30%-40% rate of current gold-standard devices.
Ceretrieve's device allows single-pass clot removal and full blood flow restoration, ensuring high safety by minimizing the risk of clot fragments moving further into the brain.
The technology demonstrated superior performance compared to existing devices, highlighting its potential to significantly improve post-stroke patient outcomes.
Limaca Medical announced the successful completion of 24 cases using its Precision-GI™ endoscopic ultrasound guided motorized fine needle biopsy (EUS-mFNB) device on May 15, 2024. The device, used in both pancreatic and liver biopsies, showed significant tissue acquisition capabilities. Six cases involved the pancreas and eighteen the liver. Two-thirds of the cases were completed with a single needle pass, achieving top-grade biopsy samples in 21 out of 24 cases. The Precision-GI™ device, designed to obtain biopsies for definitive diagnoses of gastrointestinal cancers, has received FDA Clearance and Breakthrough Device Designation. Dr. Carlos Robles-Medranda, who led the study, praised the device for its efficiency and quality of biopsy tissue obtained.
ZygoFix, a Trendlines portfolio company, has received FDA clearance for its zLOCK Lumbar Facet Fixation System, revolutionizing spinal fusion surgery. The system, backed by strong clinical evidence, offers a minimally invasive procedure with long-term pain reduction benefits. With CE certification and successful clinical utilization, ZygoFix is poised to make a significant impact in the US market.
Arcuro Medical appointed Jamal Rushdy, a seasoned MedTech industry veteran, as its new CEO. Rushdy brings over 28 years of experience in orthopedics and sports medicine. The company aims to enhance patient care with their SuperBall™ technology for meniscus repair. Lee Ranon, the co-founder, transitions to the COO role. The board expresses confidence in Rushdy's leadership for the company's growth.
FAQ
What is the current stock price of THE TRENDLINES GRP SP/ADR (TRNLY)?
What is the market cap of THE TRENDLINES GRP SP/ADR (TRNLY)?
What is The Trendlines Group SP/ADR (TRNLY)?
What sectors does The Trendlines Group focus on?
What recent investments has The Trendlines Group made?
What is the core business of The Trendlines Group?